CMTA_2020_Annual_Report

…projects, it is important to keep in mind that we have a clear pathway for treatment of CMT2 type neuropathies that affect motor neurons. The recently approved AAV treatment for…

CMTA Staff

Dr. Suzanne (Sue) Bruhn | she/her Chief Executive Officer Sue has dedicated her career to patient-focused drug development for the treatment of rare diseases. She’s had a long career in…

CMTA Centers of Excellence

CLINICAL EXPERTISE, COMPREHENSIVE EVALUATION AND CARE, INFORMATION CRUCIAL FOR CLINICAL TRIALS CMTA’s community-led, community-driven mission is to support the development of new treatments for Charcot-Marie-Tooth disease (CMT), to improve the…

Genetics

…in a CLIA-certified lab before the information could be used for clinical purposes (such as treatment or clinical trials). Instead, get tested at a genetic testing company because they do…

2018_Winter_CMTA_Report

…consulted for treatment. Neuropathic and musculoskeletal pain are different in nature, and different strategies can be used to manage them. Cramps can be persistent, but, unfortunately, evidence is lacking on…

The Art of Letting Go

…a cane and fend for himself. “I won’t be here forever,” she repeatedly told him. Harsh though her treatment of the young Ray Charles seemed, their story is filled with…

NJ/NYC Focus Group with Acceleron Pharma

…furthering the development of treatments, and ultimately a cure, for CMT. One of the first CMTA Patients as Partners in Research projects was a focus group coordinated in partnership with…

Seattle Focus Group with Acceleron Pharma

…the work of our Strategy to Accelerate Research (STAR) and showcase ways the patient community can participate in furthering the development of treatments, and ultimately a cure, for CMT. As…